13:03:04 EDT Fri 07 May 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:INCY - INCYTE CORPORATION - http://www.incyte.com13:03:04 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
INCY - Q0.282.46·82.510.182.485+0.1750.2309.825,8617,44282.19  84.26  82.19110.365  75.5212:37:50May 0415 min RT 2¢

Recent Trades - Last 10 of 7442
Time ETExPriceChangeVolume
12:37:50Q82.4850.175100
12:37:46Q82.4850.17513
12:37:40Q82.4850.175100
12:37:35Q82.4850.17521
12:37:32Q82.4850.17537
12:37:32Q82.4850.1752
12:37:32Q82.4850.175140
12:37:32Q82.470.161
12:37:31Q82.480.17100
12:37:30Q82.4650.155100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent BulletinsNews ReleasesIn The NewsOther
Date ETSymbolTypeHeadline
2021-05-04 07:00U:INCYNews ReleaseIncyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
2021-05-03 08:00U:INCYNews ReleaseIncyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021
2021-04-27 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conference
2021-04-23 10:01U:INCYNews ReleaseOLUMIANT ® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses
2021-04-23 10:00U:INCYNews ReleaseIncyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
2021-04-23 10:00U:INCYNews ReleaseIncyte Announces New Findings from Pooled Analyses of the Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients with Atopic Dermatitis
2021-04-20 08:00U:INCYNews ReleaseMultiple Abstracts from Incyte ’s Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience
2021-04-20 06:45U:INCYNews ReleaseLilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
2021-04-19 16:01U:INCYNews ReleaseIncyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
2021-04-13 08:00U:INCYNews ReleaseIncyte to Report First Quarter Financial Results